Evaluating a new imaging technique for liver cancer
Official title: Single Centre Prospective Evaluation of 68Gallium-FAPI PET/MRI in Hepatocellular Carcinoma
Run by National University Hospital, Singapore · NCT05687747 · Data updated 2026-11-12
This study is testing a new type of scan to see if it can better detect and understand liver cancer in patients compared to standard imaging methods.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 21 Years to 99 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | National University Hospital, Singapore Academic / other |
| Locations | 1 site (Singapore) |
| Status | Recruiting |
| Started | August 18, 2023 |
| Main results expected | August 2025 |
| Study ends | February 2026 |
| Registry record updated | April 4, 2025 |
| Trial ID | NCT05687747 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 21-99 with a confirmed diagnosis of Hepatocellular Carcinoma who have not undergone prior locoregional therapy.
✕Probably not a fit
Patients with known active malignancies other than HCC or those who have had recent hepatic surgery may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of 68Gallium-FAPI-46 PET/MRI in patients diagnosed with Hepatocellular Carcinoma (HCC). Patients will undergo both the PET/MRI scan and standard contrasted multiphasic MRI imaging to compare the results. The goal is to assess the new imaging technique's ability to detect, characterize, and stage liver lesions more accurately than traditional methods. This is a single-center, prospective evaluation aimed at improving diagnostic approaches for HCC.
Why it matters
Potential benefit: If successful, this study could lead to more accurate detection and staging of liver cancer, potentially improving treatment outcomes for patients.
How similar studies have gone: While the use of PET/MRI in cancer imaging is gaining traction, this specific approach with 68Gallium-FAPI-46 is relatively novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 21-99 years * Diagnosis of HCC based on histological assessment, or meeting consensus radiological criteria for diagnosis of HCC based on American Association for the Study of Liver Diseases practice guidelines(18) * No prior locoregional therapy for HCC * Creatinine clearance \> 30ml/min based on Cockcroft Gault formula * Able to provide informed signed consent Exclusion Criteria: * Allergy to 68Ga-FAPI contrast agents * Contraindication to MRI, including but not limited to MRI incompatible metallic implants, cardiac pacemaker, claustrophobia * Weight \> 150kg * Known active malignancy other than HCC * Hepatic surgery within the last 30 days. * Active inflammatory conditions that may affect FAPI imaging in opinion of investigator. Including but not limited to active infection, IgG4-related disease, inflammatory bowel disease, * Pregnancy (all women of childbearing age are required to undertake a urine pregnancy test)
Where it's running
-
Robert John Walsh
Singapore, Singapore Recruiting
Study contacts
- Principal investigator: Robert Walsh — National University Hospital, Singapore
- Study coordinator: Robert Walsh
- Email: robert_walsh@nuhs.edu.sg
- Phone: 6908-2222
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
InstaSure Non-Invasive Finger-Press Test for HCC
This study tests a non-invasive finger-skin test to help identify hepatocellular carcinoma in adults.
-
BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer
This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.
-
Zinc add-on with targeted therapy plus immunotherapy for advanced liver cancer
This study tests whether adding daily zinc to standard targeted therapy and immunotherapy helps people with unresectable or advanced hepatocellular carcinoma.
-
68Ga-SorB PET/CT imaging for solid tumors
This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.
-
Hepatocellular Carcinoma Patient Registry (CHARM Hepatocellular Carcinoma MEA)
This observational study collects medical records of adults with hepatocellular carcinoma to understand how the disease presents and progresses across regions in the Middle East and North Africa.
-
GLP-1 RA plus standard treatment in first-line metastatic GI cancers
This early-phase trial tests whether adding a GLP-1 receptor agonist to standard first-line chemotherapy is safe and feasible for people with metastatic pancreatic, colorectal, or liver cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.